Remifentanil discontinuation and subsequent intensive care unit-acquired infection: a cohort study

Table 1 Characteristics of study patients at intensive care unit admission

Characteristic	ICU-acquired infection n = 233	No ICU-acquired infection n = 354	P value
Age	61 ± 14	57 ± 16	< 0.001
Male gender	161 (69)	244 (68)	> 0.999
SAPS II	54 ± 17	51 ± 20	< 0.001
LOD score	5.8 ± 3.6	4.6 ± 3.6	< 0.001
McCabe score			0.006
Nonfatal underlying disease	95 (40)	181 (51)
Ultimately fatal underlying disease	100 (42)	142 (40)
Rapidly fatal underlying disease	38 (16)	31 (8)
Glasgow coma score	11 ± 2	12 ± 2	0.651
Admission category			0.129
Medical	161 (69)	266 (75)
Surgical	72 (30)	88 (24)
Transfer from other wards	166 (71)	198 (55)	< 0.001*
Comorbidities
COPD	63 (27)	101 (28)	0.708
Chronic heart failure	55 (23)	72 (20)	0.358
Immunosuppression	60 (25)	68 (19)	0.066
Diabetes mellitus	34 (14)	78 (22)	0.025†
Infection	156 (66)	204 (57)	0.025‡
Prior antibiotic treatment	112 (48)	151 (42)	0.204
Length of prior hospital stay, days, median (interquartile range)	2 (0 to 6)	1 (0 to 3)	< 0.001

Data are presented as mean ± standard deviation or number (%), unless otherwise specified.
*Odds ratio = 1.95, 95% confidence interval = 1.37 to 2.77; †Odds ratio = 0.60, 95% confidence interval = 0.38 to 0.94; ‡Odds ratio = 1.49, 95% confidence interval = 1.05 to 2.10.
COPD = chronic obstructive pulmonary disease; ICU = intensive care unit; LOD = logistic organ dysfunction; SAPS = simplified acute physiology score.

ISSN: 1364-8535